Cargando…

Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology

PURPOSE: The COVID-19 pandemic has affected healthcare systems globally, leading to reorganization of medical activities. We performed an international survey aimed to investigate the medium- and long-term impact on oncology units. MATERIALS AND METHODS: An 82-item survey was distributed from June 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Onesti, Concetta Elisa, Tagliamento, Marco, Curigliano, Giuseppe, Harbeck, Nadia, Bartsch, Rupert, Wildiers, Hans, Tjan-Heijnen, Vivianne, Martin, Miguel, Rottey, Sylvie, Generali, Daniele, Campone, Mario, Cristofanilli, Massimo, Pusztai, Lajos, Peeters, Marc, Berchem, Guy, Cortes, Javier, Ruhstaller, Thomas, Ciruelos, Eva, Rugo, Hope S., Jerusalem, Guy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2021
Materias:	SPECIAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081548/ https://www.ncbi.nlm.nih.gov/pubmed/33529077 http://dx.doi.org/10.1200/GO.20.00589

Ejemplares similares

LBA76_PR Expected medium and long term impact of the COVID-19 outbreak in oncology
por: Jerusalem, G., et al.
Publicado: (2020)

Oncological care organisation during COVID-19 outbreak
por: Onesti, Concetta Elisa, et al.
Publicado: (2020)

Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy
por: Onesti, Concetta Elisa, et al.
Publicado: (2019)

Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment
por: Onesti, Concetta Elisa, et al.
Publicado: (2018)

Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse
por: Onesti, Concetta Elisa, et al.
Publicado: (2020)

Immunity and Breast Cancer: Focus on Eosinophils
por: Poncin, Aurélie, et al.
Publicado: (2021)

Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
por: Rugo, Hope S., et al.
Publicado: (2022)

Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer
por: van Abbema, Doris, et al.
Publicado: (2019)

Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study
por: Corona, Silvia P., et al.
Publicado: (2020)

Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study
por: Corona, Silvia P., et al.
Publicado: (2022)

Associations of hospital volume and hospital competition with short-term, middle-term and long-term patient outcomes after breast cancer surgery: a retrospective population-based study
por: van der Schors, Wouter, et al.
Publicado: (2022)

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
por: van Hellemond, Irene E. G., et al.
Publicado: (2018)

What to Do with Non-visualized Sentinel Nodes? A Dutch Nationwide Survey Study
por: Verheuvel, Nicole C., et al.
Publicado: (2017)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Different outcome in node-positive breast cancer patients found by axillary ultrasound or sentinel node procedure
por: Verheuvel, Nicole C., et al.
Publicado: (2017)

Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer
por: Curigliano, Giuseppe, et al.
Publicado: (2023)

Characteristics of triple-negative breast cancer
por: de Ruijter, Tim C., et al.
Publicado: (2010)

Frequency and diagnostic outcome of bilateral recall at screening mammography
por: Lameijer, Joost R. C., et al.
Publicado: (2020)

Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3
por: Rugo, Hope S., et al.
Publicado: (2021)

Gene expression profiling of breast cancer
por: Pusztai, Lajos
Publicado: (2009)

Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars
por: Stebbing, Justin, et al.
Publicado: (2020)

Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity
por: Janji, Bassam, et al.
Publicado: (2018)

Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression
por: Giuliani, Massimo, et al.
Publicado: (2017)

A role for EMT in CD73 regulation in breast cancer
por: Hasmim, Meriem, et al.
Publicado: (2022)

Development of indicators for patient-centred cancer care
por: Ouwens, Mariëlle, et al.
Publicado: (2009)

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
por: Schettini, Francesco, et al.
Publicado: (2021)

Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer
por: Lousberg, Laurence, et al.
Publicado: (2017)

Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
por: Schettini, Francesco, et al.
Publicado: (2020)

Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors
por: Truin, Wilfred, et al.
Publicado: (2017)

Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?
por: Iwamoto, Takayuki, et al.
Publicado: (2010)

Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnostics
por: Shiang, Christine, et al.
Publicado: (2010)

Geriatric screening tools are of limited value to predict decline in functional status and quality of life: results of a cohort study
por: Deckx, Laura, et al.
Publicado: (2015)

Impact of the second reader on screening outcome at blinded double reading of digital screening mammograms
por: Coolen, Angela M. P., et al.
Publicado: (2018)

Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes
por: Jerusalem, Guy, et al.
Publicado: (2014)

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
por: Hurvitz, Sara A., et al.
Publicado: (2013)

Moving Breast Cancer Therapy up a Notch
por: Mollen, Erik W. J., et al.
Publicado: (2018)

Healthcare Use during the Last Six Months of Life in Patients with Advanced Breast Cancer
por: Schmitz, Renée. S. J. M., et al.
Publicado: (2021)

Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1
por: Ciruelos, Eva Maria, et al.
Publicado: (2021)

HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
por: Jerusalem, Guy, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mrupku4nj1eqpv91qret4fji95